• Users Online: 665
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2015  |  Volume : 9  |  Issue : 4  |  Page : 144-151

Replacement of calcineurin inhibitors with everolimus: Long-term impact in renal transplant recipients – A single center study


1 Transimmun – Transplantation Immunology & Research Centre, Somajiguda, Hyderabad 500082, AP, India
2 Department of Nephrology and Transplantation, Krishna Institute of Medical Sciences, Hyderabad 500003, AP, India

Correspondence Address:
Kesiraju Sailaja
Transimmun – Transplantation Immunology & Research Centre, Somajiguda, Hyderabad 500082, AP
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.1016/j.ijt.2015.10.015

Get Permissions

Background: Calcineurin inhibitor withdrawal with introduction of mammalian target of rapamycin inhibitors is associated with improvement in the renal function. The aim of the study was to evaluate the long-term allograft function after a complete switch over to everolimus from CNI at different time points. Methods: Single center prospective, observational, follow-up study, in which 136 renal transplant patients received everolimus or continued CNI based therapy in de novo (day zero of transplantation), switch early (<6 months) and late (>6 months) groups. Patients were followed for 108 months. Results: 88 patients completed the 108-month study. At month 108, the mean mGFR was 33.94 (95% CI 42.67–57.25) ml/mt/1.73 m2 in de novo group, 49.19 (95% CI 55.29–64.99) ml/mt/1.73 m2 in early switch over, 25.95 (95% CI 34.34–7.38) ml/mt/1.73 m2 in late switch over and 34.54 (95% CI 41.57–54.06) ml/mt/1.73 m2 in CNI group. Patient and graft survival were comparable among groups (p = 0.698). There were 5 (13.1%) deaths in the de novo, 3 (10.3%) in early switch, 5 (21.7%) in late switch, and 6 (13%) in CNI group. Biopsy proven acute rejection rates were comparable among the groups: 28.9%, 20.7%, 26.7%, and 19.5% in de novo, early, late and CNI groups respectively (p = 0.057). Conclusion: Improvement in the renal function was observed in early switchover. Furthermore, patients with good renal function may benefit from conversion even at a late stage, and in patients with suboptimal renal function everolimus may not add any further benefit.


[PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed45    
    Printed5    
    Emailed0    
    PDF Downloaded15    
    Comments [Add]    

Recommend this journal